Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor.
Fuchs-Young
R
R
Skeletal Disease Research, Endocrine Division, Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, Indiana 46285, USA.
Glasebrook
A L
AL
Short
L L
LL
Draper
M W
MW
Rippy
M K
MK
Cole
H W
HW
Magee
D E
DE
Termine
J D
JD
Bryant
H U
HU
D000818:Animals; D015519:Bone Density / Q000187:drug effects; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism; D002455:Cell Division / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D004997:Ethinyl Estradiol / Q000494:pharmacology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009929:Organ Size / Q000187:drug effects; D009928:Organ Specificity; D010880:Piperidines / Q000494:pharmacology*; D020849:Raloxifene Hydrochloride; D051381:Rats; D011960:Receptors, Estrogen / Q000819:agonists* / Q000037:antagonists & inhibitors*; D013629:Tamoxifen / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D014599:Uterus / Q000033:anatomy & histology / Q000378:metabolism
D010880:Piperidines; D011960:Receptors, Estrogen; D013629:Tamoxifen; D004997:Ethinyl Estradiol; D020849:Raloxifene Hydrochloride; D002784:Cholesterol